Inhibition of Rat Hepatic Lipocyte Activation in Culture by Interferon–γ
The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.
Abstract
Hepatic lipocytes (perisinusoidal, Ito cells) are the primary matrix–producing cells in liver fibrosis. During liver injury they undergo activation, a process characterized by cell proliferation and increased fibrogenesis. We and others have established a culture model in which in vivo features of lipocyte activation can be mimicked by cells grown on plastic. Additionally, we recently showed that activation is associated with new expression of smooth muscle-specific α–actin both in vivo and in culture. Although interferon–γ is known to inhibit collagen production in some systems, its action as a general modulator of lipocyte activation has not been examined; this issue forms the basis for our study. In culture–activated lipocytes, interferon–γ (1,000 U/ml) significantly inhibited lipocyte proliferation as assessed by [3 H]thymidine incorporation assay and nuclear autoradiography. In time–course studies of activation, it also markedly reduced expression of smooth muscle-specific α–actin and its messenger RNA. In dose–response experiments, maximal inhibitory effects on smooth muscle-specific α–actin mRNA gene expression were achieved with as little as 10 U interferon–γ/ml. Inhibition of cellular activation was reversible; after interferon–γ withdrawal, messenger RNA levels of smooth muscle-specific α–actin returned to untreated control levels. The effect of interferon–γ extended to extracellular matrix gene expression, with reduction of type I collagen, type IV collagen and total fibronectin messenger RNAs to 3%, 24% and 15% of untreated control levels, respectively. In contrast to the marked effects on smooth muscle–specific α–actin and extracellular matrix gene expression, interferon–γ reduced total protein synthesis by only 17.7%. Moreover, maximal doses of interferon–γ had no effect on cell viability as determined by exclusion of propidium iodide. In summary, interferon–γ is a potent inhibitor of lipocyte activation and may prove useful in the treatment of fibrotic liver injury. (Hepatology 1992;16:776-784.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, interferon-γ (IFNγ), produced by many immune cells including NK, NKT and T cells, has direct anti-fibrogenic activity on HSCs (70–72).”
From Hepatic Stellate Cell-Immune Interactions in NASH (2022) · cites this paper as [70]
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426 · cited 1×
“guanidinium isothiocyanate by the method of Chomczynski and Sacchi (26); integrity of all samples was documented by visualization of 18s and 28s ribosomal bands after electrophoresis through a 0.”
Melton, D. A., Krieg, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K., & Green, M. R. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.18.7035 · Cited by 6,324 · cited 1×
“Radiolabeled cRNAs were generated by transcription with SP6 or T7 polymerase with [ ~ l - ~ ~ P l CTP (29).”
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Skalli, O., Ropraz, P., Trzeciak, A., Benzonana, G., Gillessen, D., & Gabbiani, G. (1986) · The Journal of cell biology · doi:10.1083/jcb.103.6.2787 · Cited by 1,621
Self-citationRoss, R. (1971) · The Journal of Cell Biology · doi:10.1083/jcb.50.1.172 · Cited by 1,569
Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction
Gabbiani, G., Ryan, G. B., & Majno, G. (1971) · Experientia · doi:10.1007/bf02147594 · Cited by 1,485
Self-citationDarby, I. A., Skalli, O., & Gabbiani, G. (1990) · PubMed · Cited by 1,189
Self-citationHepatic lipocytes: the principal collagen-producing cells of normal rat liver.
Friedman, S. L., Roll, F. J., Boyles, J., & Bissell, D. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8681 · Cited by 859 · cited 1×
“approximately 5% to 10% of total protein synthesis in activated lipocytes (39).”
Self-citationBissell, D. M., Arenson, D. M., Maher, J. J., & Roll, F. J. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112887 · Cited by 543
Self-citationJohnson, R. J., Iida, H., Alpers, C. E., Majesky, M. W., Schwartz, S. M., Pritzi, P., Gordon, K., & Gown, A. M. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115089 · Cited by 460
Research works printed but not linked: 9
- Geerts, 1990, HEPATOLOGY, 13, 1193
- Czaja, 1987, HEPATOLOGY, 7, 1047
- Enzan, 1985, Acta Pathol Jpn, 35, 1301
- Friedman, 1989, Gastroenterology, 96, a598
- Pinzani, 1990, HEPATOLOGY, 12, 920
- Mitchell, 1989, Lab Invest, 60, 643
- Kapanci, 1990, Am J Pathol, 136, 881
- Leslie, 1991, Am J Pathol, 139, 207
- Darby, 1990, Lab Invest, 63, 21
Cited by
Items 101–179 of 179
Lim, M. C. C., Maubach, G., & Zhuo, L. (2008) · Molecules and Cells · doi:10.1016/s1016-8478(23)17595-9 · Cited by 32
Cyclosporin A and FK-506 in inhibition of rat ito cell activation in vitro
Ikeda, H., & Fujiwara, K. (1995) · Hepatology · doi:10.1002/hep.1840210440 · Cited by 29
Lortat‐Jacob, H., Baltzer, F., Desmoulière, A., Peyrol, S., & Grimaud, J.-A. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80258-9 · Cited by 27
The antifibrotic role of natural killer cells in liver fibrosis
Wei, Y., Bingyu, W., Yang, L., & Yuan, X. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221092672 · Cited by 32
Li, T., Shi, Z., & Rockey, D. C. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00359.2011 · Cited by 26
Self-citationShi, Z., & Rockey, D. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164863 · Cited by 26
Self-citationBioconjugation of Oligonucleotides for Treating Liver Fibrosis
Ye, Z., Houssein, H. S. H., & Mahato, R. I. (2007) · Oligonucleotides · doi:10.1089/oli.2007.0097 · Cited by 28
Alpini, G. D., Elias, I., Glaser, S. S., Rodgers, R., Phinizy, J. L., Robertson, W. E., Francis, H., Lasater, J., Richards, M., & LeSage, G. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80184-5 · Cited by 26
Chen, M. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i26.4045 · Cited by 25
“The effects of INF-γ on collagen production have been the objects of a number of studies suggest that INF-γ acts as an endogenous mediator reducing collagen synthesis[27, 28 ].”
BackgroundLy, L. H., Smith, R., Chapkin, R. S., & McMurray, D. N. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02685.x · Cited by 29
Cheng, Q., Li, N., Chen, M., Zheng, J., Qian, Z., Wang, X., Huang, C., Li, Q., Lin, Q., & Shi, G. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.10.047 · Cited by 28
New challenges in hepatic fibrosis
Clément, B., Loréal, O., Levavasseur, F., & Guillouzo, A. (1993) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80002-9 · Cited by 25
Apoptosis and liver fibrosis: antifibrotic strategies
Calès, P. (1998) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(98)80011-5 · Cited by 23
Tarçın, O., AVŞAR, K., Demırtürk, L., Gültepe, M., Oktar, B. K., Özdogan, O. C., Tarçın, Ö., Baloğlu, H., & Gürbüz, A. K. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03004.x · Cited by 23
Paulsen, D., Urban, A., Knorr, A., Hirth‐Dietrich, C., Siegling, A., Volk, H., Mercer, A. A., Limmer, A., Schumak, B., Knolle, P. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074605 · Cited by 23
“The antifibrotic effect is mediated by the ability of IFN-c to suppress the overexpression of TGFß mRNA, which is followed by the suppression of procollagen mRNAs [45–49].”
BackgroundEffect of natural interferon α on proliferation and apoptosis of hepatic stellate cells
Ogawa, T., Kawada, N., & Ikeda, K. (2009) · Hepatology International · doi:10.1007/s12072-009-9129-y · Cited by 26
“Initially, IFNc was reported to successfully inhibit HSC activation, as revealed by its inhibitory effect on collagen synthesis and smooth muscle a-actin expression [25, 26].”
BackgroundCross-talk between hepatic stellate cells and T lymphocytes in liver fibrosis
Li, H., Ding, P., Peng, B., & Ming, Y. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.04.007 · Cited by 23
Developing strategies for liver fibrosis treatment
Murphy, F. R., Arthur, M. J. P., & Iredale, J. P. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.11.1575 · Cited by 20
“IFN-γ also reduces activation and collagen synthesis by stellate cells and fibrosis in experimental animal models [84-86].”
BackgroundAction of endothelins on hepatic stellate cells
Kawada, N., Kuroki, T., Kobayashi, K., Inoue, M., Kaneda, K., & Decker, K. (1995) · Journal of Gastroenterology · doi:10.1007/bf02349639 · Cited by 23
Interplay of Matrix and Myofibroblasts During Hepatic Fibrogenesis
Schuppan, D., Cho, J. J., Jia, J., & Hahn, E. G. (1999) · Current topics in pathology · doi:10.1007/978-3-642-58456-5_21 · Cited by 20
Hepatic Fibrosis and Cirrhosis
Rockey, D. C., & Friedman, S. L. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50011-5 · Cited by 36
Self-citationPapatheodoridis, G., & Cholongitas, Ε. (2004) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2004.00522.x · Cited by 20
Giannopoulou, M., Iszkula, S. C., Dai, C., Tan, X., Yang, J., Michalopoulos, G. K., & Liu, Y. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00388.2005 · Cited by 18
Nephroblastoma overexpressed gene (NOV) expression in rat hepatic stellate cells
Lee, S. H., Seo, G. S., Park, Y. N., & Sohn, D. H. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.06.009 · Cited by 17
Salvati, A. L., & Poelstra, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010217 · Cited by 18
Tang, J. T. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i19.3015 · Cited by 16
Poelstra, K., Beljaars, L., & Melgert, B. N. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.013 · Cited by 19
Regulation of stellate cell proliferation by lipopolysaccharide: Role of endogenous nitric oxide
Kawada, N., Seki, S., Kuroki, T., & Inoue, M. (1998) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.1998.13.s1.6 · Cited by 16
Human liver growth in fibrosis and cirrhosis
Wu, J. H., Kuncio, G. S., & Zern, M. Α. (1998) · Springer eBooks · doi:10.1007/978-94-011-4932-7_22 · Cited by 15
Wu, Y., Cai, W.-M., Li, Q., Liu, Y., Shen, H., Mertens, P. R., Dooley, S., & Weng, H. (2011) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(11)60024-6 · Cited by 15
Does the neuropeptide somatostatin have therapeutic potential against schistosomiasis?
Chatterjee, S., Mbaye, A. I., Man, J. G. D., & Marck, E. A. E. V. (2002) · Trends in Parasitology · doi:10.1016/s1471-4922(02)02294-8 · Cited by 15
Fujita, T., Maesawa, C., Oikawa, K., Nitta, H., Wakabayashi, G., & Masuda, T. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.17.4.605 · Cited by 19
Are we any closer to treating liver fibrosis (and if no, why not)?
Feng, R., Yuan, X., Shao, C., Ding, H., Liebe, R., & Weng, H. (2018) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12584 · Cited by 14
Lee, B. S., Kim, N. J., Jeong, H. Y., Lee, H. Y., Kang, D. Y., & Noh, S. M. (2003) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2003.18.1.6 · Cited by 14
Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development
Sánchez, P. S., Rigual, M. D. M., & Djouder, N. (2021) · Cancers · doi:10.3390/cancers13205045 · Cited by 13
“(iii) Several cytokines activate HSCs, including TNFα, IL1β, TGFβ1, IL22 (macrophages), IL-17A (Th17 cells), TGFβ1, PDGFβ (platelets) and IFNγ (NK).”
BackgroundInfluentialTherapy for hepatic fibrosis: Revisiting the preclinical models
Bissell, D. M. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.03.009 · Cited by 18
“[7] Rockey DC, Maher JJ, Jarnagin WR, Gabbiani G, Friedman”
BackgroundHepatic Fibrosis and Cirrhosis
Rockey, D. C., & Friedman, S. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00005-x · Cited by 22
Self-citationNowatzky, J., Knorr, A., Hirth‐Dietrich, C., Siegling, A., Volk, H., Limmer, A., Knolle, P. A., & Weber, O. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01086.x · Cited by 16
Song, Y., Chen, X., Kong, X., Liu, N., Li, W., Wu, X., Lin, J., & Jin, Y. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.744 · Cited by 12
Consequences of Amyloid‐β Deficiency for the Liver
Buniatian, G. H., Schwinghammer, U., Tremmel, R., Cynis, H., Weiß, T. S., Weiskirchen, R., Lauschke, V. M., Youhanna, S. C., Ramos, I., Valcárcel, M., et al. (2024) · Advanced Science · doi:10.1002/advs.202307734 · Cited by 10
Self-citationImmune cells and immune cell-targeted therapy in chronic pancreatitis
Zhang, Y., Zhang, W., Liu, X., Zhang, Q., Mao, T., & Li, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1151103 · Cited by 13
Lee, S. H., Seo, G. S., Park, P., Choi, J.-Y., Park, Y. N., Kim, H. K., Chae, K., & Sohn, D. H. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00448-0 · Cited by 10
Abe, S., Narita, R., Hiura, M., Jia, D. M., Tabaru, A., & Otsuki, M. (2004) · Journal of Gastroenterology · doi:10.1007/s00535-003-1286-5 · Cited by 9
Inflammation and Hepatotoxicity
Luyendyk, J. P., Roth, R. A., & Ganey, P. E. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.01031-9 · Cited by 10
Nan, J., Park, E. J., Lee, S. H., Park, P. H., Kim, J. Y., Ko, G., & Sohn, D. H. (2000) · Archives of Pharmacal Research · doi:10.1007/bf02976580 · Cited by 8
Zoheir, K. M. A., Amara, A. A. A. F., Ahmad, S. F., Mohammad, M. A., Ashour, A. E., Harisa, G. I., & Abd‐Allah, A. R. A. (2014) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2014.11.001 · Cited by 8
Suzuki, C., Kayano, K., Uchida, K., Sakaida, I., & Okita, K. (2001) · Journal of Gastroenterology · doi:10.1007/s005350170098 · Cited by 7
Sakaida, I., & Okita, K. (1995) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1995.tb01801.x · Cited by 6
New Therapies in Hepatitis C Virus and Chronic Liver Disease: Antifibrotics
Rockey, D. C. (2006) · Clinics in Liver Disease · doi:10.1016/j.cld.2006.08.019 · Cited by 7
Self-citationInflammation and Hepatotoxicity
Luyendyk, J. P., Ganey, P. E., Fullerton, A. M., & Roth, R. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95664-2 · Cited by 5
Atsukawa, K., Saito, H., Tsukada, N., Akiba, Y., Toda, K., Kumagai, N., Ohishi, T., Kamegaya, Y., & Ishii, H. (2001) · Hepatology Research · doi:10.1016/s1386-6346(00)00133-9 · Cited by 5
Interactions of Stellate Cells with Other Non-Parenchymal Cells
Kawada, N., & Parola, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800134-9.00012-9 · Cited by 8
Tgf-β and the Smad Pathway in Liver Fibrogenesis
Gressner, A. M., Dooley, S., & Weiskirchen, R. (2005) · Springer eBooks · doi:10.1007/3-540-27194-5_12 · Cited by 5
“In liver, the potential of IFN-γ to counteract activation of HSC has been shown [6, 75].”
BackgroundWas bringt die Interferontherapie bei der chronischen Hepatitis?
Böker, K. H. W., & Manns, M. P. (1997) · Der Internist · doi:10.1007/s001080050131 · Cited by 4
Chen, Y., Du, B., Zheng, Z., Xiang, G., Liu, X.-B., & Mai, G. (2012) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(12)60163-5 · Cited by 3
Schuppan, D., & Hahn, E. G. (1998) · Springer eBooks · doi:10.1007/978-94-011-4884-9_8 · Cited by 3
Mexican infants with extrahepatic biliary atresia display different fibrosis activity
Fabre, Y. (2004) · Hepatology Research · doi:10.1016/j.hepres.2003.10.004 · Cited by 4
“Our data correlates with in vitro experiments where IFN- has been shown to have a potent antiproliferative effect on isolated cultures of collagen-producing liver cells [ 25 ].”
ResultBode, C., Bode, J. C., Hahn, E. G., Rossol, S., Schäfer, C., & Schuppan, D. (2002) · Springer eBooks · doi:10.1007/978-3-642-56253-2_16 · Cited by 4
Current status of immunomodulatory therapies in HCV infection
Pockros, P. J. (2004) · Current Hepatology Reports · doi:10.1007/s11901-004-0004-y · Cited by 2
Bansal, M. B., & Friedman, S. L. (2005) · Humana Press eBooks · doi:10.1007/978-1-59259-885-4_29 · Cited by 1
Self-citationImmunopathogenesis of Liver Cirrhosis
Guillot, A., & Gao, B. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_35 · Cited by 1
Successful Postoperative Management of Gastrointestinal Stromal Tumor in a Dog
Lee, K., Kim, K., Yang, C.-H., Suh, G., & Lee, C. (2021) · Journal of Veterinary Clinics · doi:10.17555/jvc.2021.38.4.184 · Cited by 1
Caractérisation ultrasonore multiparamétrique du foie humain : corrélation microscopique
Wahab, A., & Hakim, A. W. A. (2004) · Cited by 1
Proliferation of Hepatic Stellate Cells and Lipid Peroxidation: Changes Due to Polyphenols.
Svegliati‐Baroni, G., Ambrosio, L., Ferretti, G., Biondi, P., Casini, A., Sario, A. D., Saccomanno, S., Jézéquel, A. M., Benedetti, A., & Orlandi, F. (1996) · Springer eBooks · doi:10.1007/978-94-009-0357-9_11 · Cited by 1
Ferrer, A. P. (2005) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Diagnosis and Treatment of Hepatic Fibrosis and Hepatic Sinusoidal Cells
Ueno, T., Tamaki, S., Sugawara, H., Sujaku, K., Ogata, R., Kim, K., Torimura, T., Sata, M., & Tanikawa, K. (1999) · Springer eBooks · doi:10.1007/978-4-431-67935-6_21
INTERFERON-?? FOR HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C
Rotman, Y., & Ghany, M. G. (2007) · Evidence-Based Gastroenterology · doi:10.1097/ebg.0b013e3181462c77
Attacking the Hepatitis C Virus with New Mechanisms of Action: Drugs in the Pipeline
Pockros, P. J. (2004)
Mexican infants with extrahepatic biliary atresia display
Fabre, Y., Bueno‐Topete, M. R., Rincón‐Sánchez, A. R., Saldaña-Cortés, J., Vargas, R., & Armendáriz‐Borunda, J. (2003)
Schuppan, D., & Hahn, E. G. (1998)
León‐Buitimea, A., Leija-Salas, A., Fariña, G. I. G., Reyes-Esparza, J. A., & Rodríguez‐Fragoso, L. (2006) · REVISTA BIOMÉDICA · doi:10.32776/revbiomed.v17i3.457
“Esta observación ha conducido al concepto que los IFNα y β son primariamente agentes antivirales con algunos efectos inmunomoduladores, pero el IFNγ es primariamente un agente inmunomodulador con poco efecto antiviral (42).”
BackgroundAntifibrotic effects of oriental herbs GLM001 on liver cirrhosis induced by bile duct ligation
Jeong, B. K. T. S. Y. J. (2002) · Oriental Pharmacy and Experimental Medicine · doi:10.3742/opem.2002.2.2.094
Punyadasa, A. C. A. C. Y., Lai, P. B. S., Leow, C. K., Lau, W. Y., & LI, A. K. C. (1999) · HPB · doi:10.1016/s1365-182x(17)30642-1
Susceptibility to Infection and Severe Disease in Schistosomiasis
Arnaud, V., & Chevillard, C. (2006) · CRC Press eBooks · doi:10.1201/9781420005325.ch29
Ex vivo Boosted Immune Cell Therapy for Canine Hepatic Disease
Bae, S., & Oh, T. (2021) · Journal of Veterinary Clinics · doi:10.17555/jvc.2021.38.4.179
“In several studies, the injection of IFN-γ inhibits liver fibrosis in experimental animals through several mechanisms besides IFN-γ suppression of TGF-β expression (2,21,22,30).”
Bode, C., Bode, J. C., Hahn, E. G., Rossol, S., Schäfer, C., & Schuppan, D. (1999) · Springer eBooks · doi:10.1007/978-3-662-05657-8_19
Inflammation and Hepatotoxicity
Luyendyk, J. P., Ganey, P. E., Fullerton, A. M., & Roth, R. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00211-4
Inhibitory Effects of the Herbal Medicine Sho-saiko-to on Liver Fibrosis
Kayano, K., Sakaida, I., & Okita, K. (2001) · Springer eBooks · doi:10.1007/978-4-431-68343-8_6
Metadata
- Authors
- Rockey, D. C., Maher, J. J., Jarnagin, W. R., Gabbiani, G., & Friedman, S. L.
- Affiliations
- San Francisco General Hospital (US)
- University of Geneva (CH)
- Corresponding author
- Rockey, Don C.
- Venue
- Hepatology
- Published
- 1992-09
- Volume
- 16
- Issue
- 3
- Pages
- 776-784
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2124972297
- Cited by
- 179
- References
- 60
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 4 · 2020: 1 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 3 · 2013: 4 · 2012: 6
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 8400 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01aa007810-12)
- National Institute on Alcohol Abuse and Alcoholism (AA07810)
- National Institute of Diabetes and Digestive and Kidney Diseases (F32 DK 08680-01, T32DK007573, T32-DK07573, P30DK026743)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- interferon-gamma, hepatic stellate cells, liver fibrosis, extracellular matrix gene expression, type I collagen, type IV collagen, fibronectin, cell proliferation
- MeSH terms
- Actins, Adipose Tissue, Animals, Cell Division, Cells, Cultured, Collagen, Extracellular Matrix, Interferon-gamma, Liver, Male, Muscle, Smooth, Rats, Inbred Strains, RNA, Messenger, Protein Biosynthesis, Gene Expression, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.